News and Events

NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology

Oct 5, 2021

NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy for cystic fibrosis (CF)

Sep 23, 2021

NovaBiotics Highlights Advantages of Novel Immune-Based Approach to Combatting Fungal and Bacterial Infectious Diseases at Peptide Therapeutics Forum 2021

Aug 25, 2021

NovaBiotics Announces Presentation at Upcoming Peptide Therapeutics Forum 2021

Aug 2, 2021

NovaBiotics Named as One of Scotland’s Top Ten Biotech Companies to Watch Out For

Jul 7, 2021

NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia

Jun 21, 2021

NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy

Jun 1, 2021

NovaBiotics attending the BIO Digital Meeting, June 2021

May 21, 2021

Clear and unbiased facts about why the COVID 19/Pneumonia relationship is bad news

Mar 30, 2021

Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics

Feb 26, 2021